Bone Marrow TransplantationTransplantation, HomologousHematopoietic Stem Cell TransplantationStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousBone MarrowHematologic NeoplasmsTransplantation ChimeraBone Marrow CellsPeripheral Blood Stem Cell TransplantationTissue DonorsBusulfanWhole-Body IrradiationStem CellsTreatment OutcomeGraft SurvivalLeukemiaRecurrenceRemission InductionGraft vs Leukemia EffectHistocompatibility TestingLiver TransplantationGraft vs Tumor EffectHematopoietic Stem CellsMyeloablative AgonistsAnemia, AplasticLeukemia, Myeloid, AcuteImmunosuppressive AgentsHistocompatibilityCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveVidarabineLymphocyte TransfusionCyclophosphamideRetrospective StudiesLymphocyte DepletionPrecursor Cell Lymphoblastic Leukemia-LymphomaMultiple MyelomaCytomegalovirus InfectionsSurvival AnalysisMyelodysplastic SyndromesKidney TransplantationHepatic Veno-Occlusive DiseaseCord Blood Stem Cell TransplantationDisease-Free SurvivalTime FactorsSurvival RateBone and BonesMinor Histocompatibility AntigensAntilymphocyte SerumSalvage TherapySiblingsTransplantation, IsogeneicMelphalanAcute DiseaseT-LymphocytesNeoplasm, ResidualAntineoplastic Combined Chemotherapy ProtocolsTransplantation ImmunologyHLA AntigensChimerismImmunosuppressionLeukemia, MyeloidBone Marrow PurgingGraft RejectionHematologic DiseasesVirus ActivationFollow-Up StudiesLymphoma, Non-HodgkinHematopoietic Stem Cell MobilizationCell TransplantationMesenchymal Stem Cell TransplantationHeart TransplantationHematopoiesisLeukocyte TransfusionCytarabineMice, Inbred C57BLAntigens, CD34PrognosisCytomegalovirusNuclear FamilyCyclosporinePrimary MyelofibrosisLung TransplantationHodgkin DiseaseGranulocyte Colony-Stimulating FactorCell DifferentiationBone Marrow DiseasesActuarial AnalysisImmunocompromised HostLymphoproliferative DisordersFatal OutcomeLeukemia, Myeloid, Accelerated PhaseInfectionRadiation ChimeraFlow CytometryOrgan TransplantationEtoposide